Connect with us


UK hospital launches ‘world-first’ endometriosis study

Researchers will evaluate the safety and effectiveness of an antibody designed to reduce inflammation and endometriosis symptoms



Matilda-Matthews, Paul Simpson, Edward Morris and Amy Nichols are running the endometriosis study

A UK hospital has launched a “world-first” endometriosis drug trial that could pave the way for new ways to manage and treat the condition.

The study, taking place at the Norfolk and Norwich University Hospital (NNUH), consists of a non-hormonal drug trial that will investigate whether it could reverse the debilitating symptoms of endometriosis and reduce the need for surgery.

Endometriosis affects one in 10 women in the UK and occurs when cells similar to those lining the womb are found elsewhere in the body. It can cause painful symptoms, including heavy periods, pelvic pain and in extreme cases scarring and damage to the pelvic organs.

Currently, there is no cure for endometriosis. Medications to reduce the severity of the symptoms range from pain relief drugs to hormonal treatments that suppress ovulation and periods.

As part of a Phase II research study, the gynaecology and research and development team at NNUH aim to evaluate the safety and effectiveness of an antibody designed to reduce inflammation and endometriosis symptoms.

The antibody, called AMY109, has been developed by scientists from Chugai Pharmaceutical Co Ltd. The drug blocks a protein (interleukin-8) which promotes the body’s inflammatory response to endometriosis.

“Patients with endometriosis have inflammation, which is a key component in disease progression and if it goes on long enough it damages tissues,” said Edward Morris, consultant gynaecologist, NHS East of England medical director and UK chief investigator on the study.

“Significant new drugs for endometriosis have not come along for decades and the ones we have in daily usage are largely hormone based, which can have unpleasant side effects.

“The way that AMY109 works in reducing inflammation and potentially the destructive scarring of endometriosis could mean in the long-term that some women may avoid surgery for this debilitating disease.

“Whilst this is the first detailed study of a drug such as this on endometriosis, it is still early days and is likely to take several years from the realisation of a drug to it becoming readily available.”

Paul Simpson, consultant gynaecologist and principal investigator at NNUH, said: “Everything so far in the treatment of endometriosis has suppressed the disease symptoms, but this new drug addresses inflammation and potentially reverse the effects of endometriosis without the need for surgery.

“It is different to every other available treatment for endometriosis because it could be disease modifying. Antibody based treatments are widely used in healthcare for treating some cancers and chronic inflammatory conditions such as, rheumatoid arthritis and inflammatory bowel disease.”

Emma Cox, CEO of Endometriosis UK, said: “The need for more investment in research into endometriosis cannot be overstated. Left untreated, endometriosis may progress. Yet current options are limited to surgery, hormonal management, or pain killers for the chronic and often severe pelvic pain that is a symptom of the disease.

“Whilst this potential new drug is at an early stage in its development, the researchers hope it will not only reduce inflammation caused by endometriosis but may potentially reduce scarring that has already occurred. With the added benefit of being non-hormonal it could be also available to those for who contraceptives are not suitable.”

She added: “Whilst it is early days in the research process, it’s great to see much needed investment in novel new ways to manage and treat endometriosis. We look forward to seeing the outcomes of this clinical trial.”

The hospital is looking for more women to get involved in the study.

Participants need to be:

  • Female and aged between 18 and 49
  • Have endometriosis previously diagnosed by laparoscopy
  • Be prepared to have further laparoscopic surgery after the study

For more information, email [email protected].


Firm secures US$1.9m grant to support women entrepreneurs in Africa

eha Impact Ventures aims to support women-owned small- and medium-sized enterprises



Evelyn Castle, chief executive officer at eHA Impact Ventures / Source:

The impact investing enterprise eHA Impact Ventures (EIV) has been awarded a US$1.9m grant from the non-profit organisation eHealth Africa (eHA) to support women entrepreneurs in Africa.

eHA’s board of directors approved the donation as part of its effort to “strengthen” healthcare delivery systems and support vulnerable populations.

The grant, the organisation said, will be deployed to “upscale” women-funded companies to improve the health and wealth of African women, their families and their communities.

The donation is hoped to address the US$42bn funding gap for women entrepreneurs in Africa and help female founders have better access to funding opportunities.

In addition, the funds are expected to support health interventions like the pre-screening of cervical cancer and improve delivery of blood and blood products to healthcare facilities.

“The grant will be instrumental in boosting the economic capacity of women across Africa by supporting high-impact women-owned businesses,” said Evelyn Castle, chief executive officer at EIV, who founded the firm in 2021.

“Furthermore, it will [help us] upscale funding, mentorship and training programmes to help women create thriving businesses that drive economic growth in their communities.”

My Le, board executive at eHealth Africa, said: “These donations could not have come at a better time as  women continue to struggle to meet up with both health and economic demands. Thus we are optimistic that the funds will go a mile in bridging fiscal gaps for women and other vulnerable groups to lead healthier lives.

“Supporting women will go a long way in not just improving their societal impact but also contribute immensely to sustainable development especially in the African region.”

Recognising women’s “vital” role in building strong health systems, Atef Fawaz, CEO of eHealth Africa, added: “We acknowledge the profound impact women have in strengthening healthcare systems, aligning with our vision at eHealth Africa.”

To receive the Femtech World newsletter, sign up here.

Continue Reading


Menstrual product wins innovation award in Switzerland

Egal’s innovation consists of a roll of pads that operates in a similar fashion to a toilet paper roll and comes in its own dispenser



Penelope Finnie, chief executive officer at Egal

Pads on a Roll, a menstrual product that can be dispensed in public stalls similar to a toilet paper roll, has won a prestigious award at the Women’s Health Innovation Summit Europe in Basel. 

Each year the Women’s Health Innovation Summit (WHIS) helps promising start-ups raise their brand awareness and pitch their solutions in front of investors and industry leaders.

Egal, the company behind Pads on a Roll, has been honoured with this year’s Women’s Health Innovation award after the WHIS selection committee recognised the start-up as an innovative company poised to disrupt the European women’s health landscape.

“Egal Pads is so honoured to have been chosen for the Women’s Health Innovation Award,” Penelope Finnie, Egal chief executive officer, told Femtech World.

“The other nine finalists were amazing companies run by wonderful people. The whole conference was a testament to the importance of the femtech movement.

“For us, it was particularly exciting as the EU is the next market we are focusing on. We hope that having period products available in stalls just like toilet paper is, will become the norm as it is necessary for equality.

“We also hope that by winning, it brings attention to this easily solved but long ignored issue,” Finnie added.

Egal’s innovation consists of a roll of pads that operates in a similar fashion to a toilet paper roll and comes in its own dispenser.

Egal aims to sell Pads on a Roll to universities and public schools

Each roll contains 40 pads and can be placed directly in stalls, unlike the typical tampon dispensers that often require money to access the products and are located outside the stall.

The pads are less expensive to maintain than products in vending machines because they are easier to refill, and require less space and packaging.

Research shows that 20 percent of girls in the US and UK have missed school due to lack of access to period products, with more than 90 per cent of menstruators having experienced jammed, broken or empty dispensers in public toilets.

Egal aims to solve this issue by selling Pads on a Roll to universities and public schools.

The Boston-based company has done pilots at various universities across the US and is hoping to develop a flushable version of the product in the future.

To receive the Femtech World newsletter, sign up here.

Continue Reading


‘It’s hard to stay healthy’- experts raise alarm over ‘pervasive’ economic challenges in US

A report highlighting women’s struggle with economic stress in the US has prompted experts to demand change



Experts have raised concerns over the “pervasive” economic and health challenges women in the US are facing, after a damning report exposed significant financial stress.

national survey of women over 25 has found that American women face significant economic stress, with half of women reporting feeling “uncertain” or “worried” when thinking about how to pay for healthcare later in life and low-income and rural women reporting challenges to staying healthy today.

The report, which highlighted financial difficulties among women for the second year in a row, has prompted experts to speak out and demand change.

“The recent findings from the National Council on Aging (NCOA) and Women’s Institute for a Secure Retirement (WISER) underscore the pervasive economic and health challenges confronting American women, particularly those from low-income and rural communities,” Georgie Kovacs, women’s health expert and founder of Fempower Health, told Femtech World.

“Many women juggle caregiving responsibilities for their children while managing employment, often in environments that offer limited support.

“The scarcity of healthy food options in low-income areas, coupled with restricted access to essential healthcare services, exacerbates their daily struggles, impacting both their mental and physical health and that of their families.”

Underlining the “profound” impact of the menopause transition, Kovacs said women across the country are in desperate need of enhanced workplace policies and better access to specialised care.

“Our approach to addressing these challenges cannot be piecemeal – we require comprehensive systems that integrate childcare, health services, job security and mental health support, ensuring that no aspect of a woman’s health is overlooked,” she explained.

“It is imperative that we view the economic insecurities faced by women through a holistic lens, recognising the interconnectedness of health, employment and wellbeing.

“It’s time for all stakeholders, including government bodies and private sectors, to unite in crafting and implementing solutions that are as multifaceted as the lives of the women they aim to support.”

Katie Higgins, chief commercial officer at fertility benefits platform Progyny, called on employers to do more to support women, arguing that the pressure of financial uncertainty could “erode” self-esteem, strain relationships and compound parental stress.

“Balancing financial pressures with caregiving responsibilities can heighten feelings of guilt and inadequacy, impacting maternal mental health.

“Employers play a vital role in empowering women to prioritise their health without financial barriers through comprehensive benefits that include family building, fertility, maternal leave and menopause.”

Lois Quam, chief executive officer at sexual and reproductive health organisation Pathfinder International, noted that there is an important connection between health and income, meaning that women with the least financial resources often find themselves unable to access health services and modern innovations.

“From rural areas to the wealthiest cities in the world, women everywhere are being left behind. In the US and globally, they get paid and promoted less than men and leave the workforce at greater numbers to raise their children.

“Closing the gender pay gap could help keep women in the workforce, especially when childcare is so costly and inaccessible,” she told Femtech World.

Author and women’s health expert, Dr Mindy Pelz, encouraged women to “take control” of their health.

“It’s hard to stay healthy, even without the added pressure of economic stress,” she said.

“Many women just can’t rely on the American healthcare system to take care of them. That’s why I’m such an advocate for taking your health into your own hands.

“Simple lifestyle changes like intermittent fasting, meditation, cold exposure, walking 10,000 steps a day, avoiding electronics before bed might seem small on their own, but if you add them together and are consistent with them over time, they can make a huge difference.”

To receive the Femtech World newsletter, sign up here.

Continue Reading


Copyright © 2023 Aspect Publishing Ltd. All Rights Reserved.